

Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia

Tom D Y Reijnders 💿 ,¹ Pierre-François Laterre,² Bruno François,³ Miguel Sánchez García,⁴ Tjitske S R van Engelen,¹ Daoud Sie,⁵ Brendon P Scicluna,^{1,6,7} Dmitry V Ostanin,⁸ Kevin J Galinsky,⁸ Joe M Butler,¹ Eleuterio Lombardo,⁹ Tom van der Poll ⁽ⁱ⁾,^{1,10} SEPCELL study group

ABSTRACT

¹Center for Experimental and Molecular Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands ²Department of Intensive Care Medicine, Université Catholique de Louvain, Louvain-la-Neuve, Belaium ³Intensive care unit and Inserm

CIC 1435 & UMR 1092. University Hospital Centre of Limoges, Limoges, France ⁴Critical Care Department, San Carlos Clinic Hospital, Madrid, Spain

⁵Department of Human Genetics, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands ⁶Center for Molecular Medicine and Biobanking, University of Malta, Msida, Malta ⁷Department of Applied Biomedical Science, University of Malta, Msida, Malta ⁸Translational Biomarker Research, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA ⁹Takeda Madrid Cell Therapy Technology Center, Tres Cantos, Spain ¹⁰Division of Infectious Diseases, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands

Correspondence to

Tom D Y Reiinders: t.d.reijnders@amsterdamumc.nl

Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Reijnders TDY,
Laterre P-F, François B, et al.
Thorax 2024;79:1086-1090.

Mesenchymal stem cells (MSC) have immune regulatory properties that may ameliorate pathophysiological processes in sepsis. We determined the effect of allogeneic adipose-derived MSCs (Cx611) on the host response during sepsis due to community-acquired bacterial pneumonia (CABP) by measuring 29 plasma biomarkers and blood transcriptomes at six time points in 82 patients randomised to two intravenous infusions of Cx611 or placebo. Cx611 treatment enhanced several endothelial cell and procoagulant response plasma biomarkers, and led to increased expression of pathways related to innate immunity, haemostasis and apoptosis. Cx611 infusion in sepsis due to CABP is associated with broad host response alterations.

INTRODUCTION

In spite of decades-long efforts, therapeutics capable of ameliorating disease pathophysiology and improving patient-important clinical outcomes in sepsis and pneumonia remain elusive. Mesenchymal stem cells (MSCs)multipotent cells that can contribute to tissue repair and modulate immune responses-exert a variety of effects on the pathophysiology of pneumonia and sepsis that have led to improved outcomes in preclinical models.¹ Several small phase I and II clinical trials have demonstrated the safety of treatment with MSCs in critically ill patients with sepsis and/or acute respiratory distress syndrome.² ³ SEPCELL was a phase Ib/ IIa clinical trial investigating the use of Cx611 (adipose-derived stem cells) in patients with severe community-acquired bacterial pneumonia (CABP), and the largest study on the effects of MSCs in this population conducted thus far.⁴⁵ We recently reported on the primary objective of SEPCELL-a favourable safety profile of Cx611 infusion in patients with severe CABP.⁵ In the current preplanned ancillary study,⁴ we aimed to assess the effect of Cx611 treatment on the host response by sequential measurements of plasma protein biomarkers-reflective

 Butler, ¹ Eleuterio Lombardo,⁹
 Protected by copyright,

 up
 of key pathophysiological processes—and blood transcriptomes.

 METHODS
 Adult patients (≥18 and ≤80 years old) were eligible for the study if there was a clinical suspicion of severe CABP, and if they needed mechanical ventilation (including high-flow oxygen) and/or vasopressor treatment. Patients were randomised to receive either two intra
were randomised to receive either two intravenous administrations of Cx611 (160×10⁶ cells) or placebo (Ringer's lactate) at day 1 and day 3 of the study. We measured 29 protein biomarkers reflective of five pathophysiological domains (inflammation, inhibition of inflammation, apoptosis, endothelial cell responses and text coagulation) before and at five time points after initiation of treatment (figure 1A, online supplemental table 1, online supplemental figure 1). We analysed the data using linear mixed models that adjusted for chance variation in baseline values between groups. Gene set enrichment analysis was done using the Reactome knowledgebase (reactome.org), focusing on predetermined pathways implicated in the pathogenesis of sepsis: immune system, apoptosis and haemoof sepsis: immune system, apoptosis and haemo-stasis. Further details on study design, inclusion and exclusion criteria, sample collection and processing, and statistical analysis can be found **g** in the online supplemental methods.

RESULTS

41 patients in both the Cx611 and placebo technologies groups participated (online supplemental figure 2). Baseline characteristics and clinical outcomes were balanced between the groups (table 1, online supplemental table 2).⁵ Figure 1B provides an overview of the effect of Cx611 infusion (relative to placebo) on all biomarkers measured in plasma obtained at five time points after treatment initiation (overview of all measurements in online supplemental table 3). The proportion of patients still in the study at the V9 time point was high and comparable between study groups (35/41 (85.4%)

1086



Figure 1 Overview of study design and effect of Cx611 treatment on plasma host response biomarkers stratified according to pathophysiological domains. (A) Overview of time points at which samples were collected for plasma protein and RNA biomarker analyses; within 18 hours of initiation of vasopressors and/or mechanical ventilation, prior to the initiation of treatment (screening/SCR), 8-12 hours following the initial infusion of Cx611 or placebo on day 1 (visit 1/V1), day 2 (V2), 8–12 hours following the second infusion of Cx611 or placebo on day 3 (V3), day 7 (V7) and day 14±2 (V9). Sample collection continued after intensive care unit (ICU) and hospital discharge. Number of samples available for plasma biomarker analyses listed to the right of each time point, Cx611-treated patients in orange, placebo-treated patients in blue/grey. (B) Heatmap showing the levels of each plasma protein host response biomarker, divided across five pathophysiological domains, for patients treated with Cx611 relative to patients treated with placebo at each time point after the initiation of treatment, expressed as an effect size (Hedges' q, red indicates higher values and blue indicates lower values in Cx611-treated patients). For visual purposes, comparisons with a Hedges' q > -0.2 and < 0.2 (considered a negligible effect) are displayed as white tiles. To account for baseline variation in biomarker levels not attributable to treatment, we used the fold change from prior to treatment (screening/SCR time point) to each time point for each patient. The p values displayed to the right of heatmap are derived from a type II Wald test on linear mixed models for each individual biomarker (as described in the statistical analysis paragraph in the online supplemental methods), and indicate whether the overall effect of Cx611 on biomarker concentrations over all time points after initiation of treatment, adjusted for baseline variation in biomarker levels, is statistically significant. These p values were adjusted for multiple testing per domain using the Benjamini-Hochberg (BH) method. CCL, CC chemokine ligand; HGF, hepatocyte growth factor; IL-1RA, interleukin 1 receptor antagonist; MMP-8, matrix metalloproteinase 8; NGAL, neutrophil gelatinase-associated lipocalin; PAI-1, plasminogen activator inhibitor 1; TNF, tumour necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; TREM-1, triggering receptor expressed on myeloid cell 1; VCAM-1, vascular cell adhesion molecule 1.

Table 1	le 1 Baseline characteristics and outcomes								
		Cx611 (n=41)	Placebo (n=41)						
Demographics									
Age, years		60.9 (11.3)	63.4 (10.4)						
Sex, male		27 (65.9%)	26 (63.4%)						
Disease seve	erity								
Randomisatio	on stratum								
Invasive mechanical ventilation		22 (53.7%)	23 (56.1%)						
Shock		14 (34.1%)	13 (31.7%)						
Both		5 (12.2%)	5 (12.2%)						
CURB-65		3 [2, 3]	3 [2, 4]						
APACHE II sco	ore	20.2 (7.7)	18.9 (6.2)						
SOFA score*		8 [7, 11]	8 [7, 9]						
Outcomes [†]									
Any thromboembolic event‡		7 (17.1%)	8 (19.5%)						
Length of intensive care unit stay		13 [6, 29]	11 [6, 19]						
Length of hospital stay		20 [12, 44]	19 [14, 36]						
28-day mortality		8 (19.5%)	6 (14.6%)						

Normally distributed continuous variables are listed as mean (SD); non-normally distributed continuous variables are listed as median [IOR]: categorical variables are listed as count (%).

*All patients fulfilled the Sepsis-3 criteria (infection plus SOFA score of 2 or higher). †A full overview of adverse events and clinical outcomes can be found in the primary clinical report.

‡Individual patients could have more than one thromboembolic event. For the Cx611 group, this included deep vein thrombosis (n=3), pulmonary embolism (n=1), cerebrovascular accident (n=2), device-related thrombosis (n=1), atrial thrombosis (n=1) and cerebral artery embolism (n=1). For the placebo group, this included deep vein thrombosis (n=5), pulmonary embolism (n=2), venous thrombosis (n=1), venous thrombosis of a limb (n=1) and jugular vein thrombosis (n=1). APACHE-II, Acute Physiology and Chronic Health Evaluation II; CURB-65, confusion, blood urea nitrogen, respiratory rate, blood pressure, age 65 or older; SOFA, Sequential Organ Failure Assessment.

for Cx611, 38/41 (92.7%); online supplemental table 1). Despite the anti-inflammatory and antiapoptotic effects of MSCs reported in preclinical studies,¹ we found few differences in biomarkers reflective of inflammation, inhibition of inflammation or apoptosis (online supplemental figures 3-5). Only tumour necrosis factor-a quintessential proinflammatory cytokine-was significantly higher in patients treated with Cx611 (p=0.030), driven by the time frame spanning stem cell infusion (V1-V3). With regard to endothelial cell biomarkers, the plasma concentrations of von Willebrand factor (reflecting endothelial cell activation), soluble thrombomodulin (endothelial cell injury) and angiopoietin-2 (disturbed barrier function) were higher in patients infused with Cx611 at time points up to V3 (ie, 8-12 hours after the second drug infusion; online supplemental figure 6). Moreover, Cx611 induced a procoagulant state in this time frame, as indicated by strong increases in the plasma levels of prothrombin fragment 1+2 (thrombin formation) and D-dimer (fibrin formation and fibrinolysis).

Analysis of blood transcriptome data revealed that Cx611 induced a predominantly proinflammatory state, detectable from day 2 after the initiation of treatment (V2) up to 4 days after the second treatment (V7; figure 2, online supplemental figure 7, online supplemental table 4). In the innate immune system pathways, we found upregulation

of pattern recognition receptor pathways such as tolllike receptors, accompanied by upregulation of pathways related to innate immune effector functions, such as neutrophil degranulation (online supplemental figure 8). Innate immune activation was further corroborated by upregulation of pathways related to key growth factors involved in emergency myelopoiesis (granulocyte and granulocytemacrophage colony-stimulating factors, and interleukin 3) and proinflammatory cytokine signalling (figure 2). In the adaptive immune system, Cx611-treated patients exhibited upregulation of pathways related to major histocom-patibility complex class I antigen presentation, suggesting activation of cellular immunity, specifically cytotoxic CD8 T cells (figure 2, online supplemental figure 8), while downregulation of pathways related to T cell receptor signalling g and reduced CD28 costimulation pointed at impaired T cell copyright activation. However, downregulation of signalling through the inhibitory immune checkpoint programmed death 1 in Cx611-treated patients argued against adaptive immunosuppression. A more detailed overview of the plasma , including biomarker and transcriptomic results—including the modest upregulation of pathways related to apoptosis, endothelial cell surface interactions and haemostasis—can be found in online supplemental figures 9 and 10.

DISCUSSION

We report the largest and most comprehensive study on the effect of MSCs on the immune response in critically ill patients, but there are limitations to consider. The study was exploratory in nature and the total intended sample size was not calculated specifically to detect differences in biomarker levels. While the risk of attrition bias is low, informative censoring due to death or withdrawal from the study may have resulted in some residual bias not fully addressed by have resulted in some residual bias not fully addressed by one linear mixed models. A replication cohort in this patient opulation did not exist at time of analysis, and the results ould therefore not be validated externally. While there were no adverse events related to Cx611 population did not exist at time of analysis, and the results could therefore not be validated externally.

٩ infusion,⁵ Cx611 treatment resulted in transient proinflammatory effects mainly relating to enhanced activation training of the endothelium and coagulation system, and increased expression of gene pathways involved in pattern recognition receptor and cytokine signalling, haemostasis and apoptosis. Our results may in part be indicative of recognition of intravenously introduced MSCs by the host immune system. The Isimi proinflammatory effects reported here contrast with the anti-inflammatory effects reported in the preponderance of preclinical studies.¹ However, previous clinical studies that reported biological outcomes were small and have not conclusively demonstrated anti-inflammatory effects of MSCs in critically ill humans.^{6–8} The adipose origin of Cx611 may play a part, but clear evidence that the immune regulatory properties of adipose-derived MSCs are different from those of MSCs of other origins is not available. Although a higher expression of tissue factor on adipose-derived MSCs⁹ could indicate a higher procoagulant potential, procoagulant responses have also been reported for MSCs of other origins.¹⁰ It remains to be established which effects of MSCs on the host response in patients with sepsis due to CABP would be beneficial for clinical outcomes, and which could potentially do harm.

for uses related

6

text

, and

	V1		v	/2		/3	V7		V9	
Immune System		0		•				-0-		
Innate Immune System	o			•				0		
C-type lectin receptors (CLRs)	o			•				0		
CLEC7A (Dectin-1) signaling	0			0		-Õ-		0	0	
Complement cascade		•		•		<u> </u>		0		
Regulation of Complement cascade		0		0		- Õ-		0	•	
Ec epsilon receptor (ECERI) signaling		0		0		-ŏ-		0	o	
FCERI mediated MAPK activation	0			0		ŏ			0	
FCERI mediated NF-kB activation		0						0	0	
Fcgamma receptor (FCGR) dependent phagocytosis			o			$-\overline{O}$				
Regulation of actin dynamics for phagocytic cup formation	0			0				-Õ-	0	
Neutrophil degranulation — — —				•				<u> </u>	•	
NLR signaling pathways				0				• •	•	
Toll-like Receptor Cascades		0							•	
Regulation of TLR by endogenous ligand		•		ō		-Ō-		ō	•	
Toll Like Receptor 10 (TLR10) Cascade		0				-Õ-		0	0	
Toll Like Receptor 2 (TLR2) Cascade		0		ō		-O-		—Ō—	0	
Toll Like Receptor 3 (TLR3) Cascade	O					- <u>O</u> -		0	- O	
Toll Like Receptor 4 (TLR4) Cascade		0				0		-0-	•	
Toll Like Receptor 5 (TLR5) Cascade		0		Ō		-Õ-		-Ō-	- o	
Toll Like Receptor 7/8 (TLR7/8) Cascade		0				-0-		-0-	0	
Toll Like Receptor 9 (TLR9) Cascade		0							0	
Cytokine Signaling in Immune system	0			•						
FL13 Signaling			0			0				
Growth normone receptor signaling	0			0		0				
Interreron Signaling	0		0	0					8	
Antiviral mechanism by IFN-stimulated genes	0		0	0			0			
Simpling by CCE2 (C CCE)	0		0			0	0			
Signaling by CSF3 (G-CSF)									0	
Signaling by Interlouking									0	
Signaling by Interleukins				K						
Interleukin-11 family signaling						K				
Interleukin 12 ranning Signaling										
Interleukin-17 Signaling	•		0						õ	
Interleukin-2 latrily signaling			0							
Interleukin-5, Interleukin-5 and GW-CST signaling									Ň	
Interleukin-4 and Interleukin-15 signaling	0								ő	
NIK poncononical NE kB signaling		lõ		Ň		Ŏ	0			
TNEs hind their physiological recentors		ľ	0					0		
			, in the second s		\cup					
Adaptive Immune System		0		0						
Class I MHC mediated antigen processing & presentation		0				-0		ŏ	•	
Antigen Presentation		0		ŏ		- Ŏ-		0	•	
Antigen processing-Cross presentation		0						•	•	
Costimulation by the CD28 family								0		
PD-1 signaling	0				-0			0		
Immunoregulatory interactions between Lymphoid & non-Lymphoid cells		0			o			•		
MHC class II antigen presentation		0		•		-0-		0		
TCR signaling	o		-			0		0		
Generation of second messenger molecules	0		- 🔾				0		•	
Phosphorylation of CD3 and TCR zeta chains	0		- ``)		0			0	•	
	_2	0 2		0 2	_2	0 2	-2	0 2	_2 0	2
	-2	0 Z	-2 (0 Z	-2	0 2	-2	0 2	-2 0	2
BH-adjusted P-val	ue		No	ormalize	d Enric	hment S	core (N	ES)		
• Not significant $\bigcirc P < 0.05$	• Not significant $\bigcirc P < 0.05 \bigcirc P < 0.01$									
	, , , , , , , , , , , , , , , , , , ,			_2	_1	1	2			

Figure 2 Significant immune system pathways from gene set enrichment analysis of the blood transcriptome. Bubble plot displaying the effect of Cx611 treatment on transcriptional pathways related to the immune system (as obtained from the Reactome knowledgebase) for each time point after the initiation of treatment with Cx611 or placebo. To adjust for chance variation in baseline gene expression between groups, the differences in gene expression at each time point are derived from the interaction terms between Cx611 and time point in linear mixed models that included the SCR time point (prior to initiation as treatment) as the reference category, and can therefore be interpreted as the difference in gene expression levels between groups at each time point relative to the gene expression levels prior to initiation of treatment. The differences in expression of genes in the listed pathways are quantified as NES and reflected in the intensity of the colour: a red bubble means higher in the Cx611-treated group, a blue bubble means lower in the Cx611-treated group and a grey bubble indicates a negligible difference. The size of the bubble is proportional to the Benjamini-Hochberg (BH)-adjusted p value for that pathway. This figure only includes pathways in which a significant difference between groups was found at one or more time points; the full version of the figure including non-significant pathways can be found in online supplemental figure 7. CLEC7A, C-type lectin domain family 7 member A; Fc, fragment crystallisable region (of an antibody); FLT3, fms-related receptor tyrosine kinase 3; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; MAPK, mitogen-activated protein kinase; MLC, major histocompatibility complex; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NIK, NF-κB-inducing kinase; NLR, nucleotide-binding domain leucine-rich repeat containing receptor; PD-1, programmed death 1; TCR, T cell receptor; TNF, tumou

Correction notice This article has been corrected since it was published Online First. A collaborator name has been corrected.

Acknowledgements We thank Desirée Perlee, PhD, for her role in the initial phases of the biomarker studies. We thank Augustijn M Klarenbeek, Jacky de Leeuw, Fayola de Lange, Barbara Dierdorp, and Tamara Dekker and the Amsterdam UMC Core Facility Genomics for their invaluable support in the laboratory and for providing HPC Genomics as high-performance compute resource. The SEPCELL study consortium is coordinated by Takeda Pharmaceuticals. The authors acknowledge the valued contribution of the investigators to the SEPCELL study.

Collaborators SEPCELL study group: Dr Christine Colienne, Dr Diego Castanares Zapatero, Dr Ludovic Gerard, Dr Philippe Hantson and Dr Virginie Montiel; Dr Jean-

Pierre Pelgrim, Dr Marco Vinetti, Dr Nicolas De Schryver and Dr Sophie Terneu; Dr Bernard Lambermont and Dr Philippe Morimont; Dr Elisabeth De Waele, Dr Joris Bart Troubleyn, Dr Jouke De Regt and Dr Patrick M Honore; Dr Manuel Álvarez González, Dr Mercedes Nieto Cabrera and Dr Ma José Jiménez; Dr Antoni-Jordi Betbesé Roig, Dr Maria Torrents Sonet, Dr Mario Antonio Alfaro Farias, Dr Miguel Ovejero Gordillo, Dr Mireia Cuartero Sala, Dr Nuria Rodriguez Farre and Dr Jaume Baldirà Martinez; Dr Cristina Pinilla, Dr Ma Asunción Romero, Dr Noemí Paredes and Dr Rosario Cuadra; Dr Adrian Ceccato, Dr Antoni Torres Marti, Dr Catia Cilloniz, Dr Cristina Dominedò and Dr Gianluigi Li Bass; Dr Adolfo Ruiz Sanmartín, Dr Alejandro Cortes Herrera, Dr Jaume Baldirà Martinez, Dr Juan Carlos Ruiz Rodriguez and Dr Sofía Contreras Medina; Dr Juan Carlos Montejo, Dr Helena Marín, Dr Ignacio Saez, Dr Silvia Chacón

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Short report

and Dr Zaida Molina; Dr Rafael Máñez Mendiluce, Dr Gabriel Moreno González and Dr Juan Carlos López Delgado; Dr Jordi Codina Calero, Dr Maria Begoña Balsera Garrido, Dr Mar Miralbés Torner, Dr Mercedes Palomar Martínez and Dr Montserrat Vallverdú Vidal; Dr Baltasar Sánchez González, Dr Carles Ferrer i Peretó and Dr Josep Trenado Álvarez; Dr Gerard Moreno Muñoz, Dr Gonzalo Sirgo Rodríguez, Dr Maria A Bodí and Dr Mònica Marget Iglesias; Dr Borja Suberviola Cañas, Dr Alejandro Gonzalez-Castro, Dr Andrés Jiménez and Dr Maite Arlabán Carpintero; Dr José Manuel Añón, Dr Alexander Agrifoglio, Dr Lucía Cachafeiro and Dr Manuel Quintana; Dr Gadea Alonso, Dr Ma Concepción García and Dr Ma Luisa Rodríguez; Dr Esther Villareal and Dr Mónica Gordon; Dr Ana Maria Navas Pérez, Dr Emilio Diaz Santos and Dr Jordi Vallés Daunis; Dr Diana Noreikiene, Dr Sandra Mazeikiene and Dr Vitalija Nausediene; Dr Pål Klepstad, Dr Hege-Merete Krabseth and Dr Johan-Arnt Hegvik; Dr Roberto Alberto De Blasi, Dr Livia Errico and Dr Maria Teresa Cirasa; Dr Anne Laure Fedou, Dr Arnaud Desachy, Dr Bruno Evrard, Dr Guillaume Gilbert, Dr Julien Vaidie, Dr Marine Goudelin, Dr Philippe Vignon and Dr Thomas Daix; Dr David Schnell, Dr Charles Lafon, Dr Christophe Cracco, Dr Gilles Lardillon, Dr Olivier Longuet, Dr Olivier Thierry Baudin, Dr Stephane Rouleau and Dr Sylvie Nicole Calvat; Dr Brian Emonet, Dr Caroline Pouplet, Dr Christine Lebert, Dr Gwenhael Colin, Dr Isabelle Vinatier, Dr Jean-Claude Lacherade and Dr Konstantinos Bachoumas; Dr Laurent Camous, Dr Laurent Martin-Lefevre, Dr Marie-Ange Azais, Dr Matthieu Henry-Lagarrique and Dr Maud Fiancette; Dr Anne Bretagnol, Dr Armelle Mathonnet, Dr Dalila Benzekri Lefèvre, Dr François Barbier, Dr Grégoire Muller, Dr Isabelle Runge, Dr Marie Skarzynski and Dr Sophie Jacquier; Professor Bertrand Souweine, Dr Armelle Gilard, Dr Claire Bachelier, Dr Elisabeth Coupez, Dr François Thouy, Dr Jean Mathias Liteaudon, Dr Marjolaine Borel and Dr Laure Calvet; Dr Charlotte Garret, Dr Jean-Baptiste Lascarrou, Dr Maëlle Martin, Dr Noëlle Brulé and Dr Laura Crosby; Dr Emmanuelle Mercier, Dr Annick Legras, Dr Antoine Guillon, Dr Charlotte Salmon-Gandonniere, Dr Denis Garrot, Dr Laetitia Bodet-Contentin, Dr Marlène Morisseau, Dr Pierre-François Dequin, Dr Stephan Ehrmann and Dr Yonatan Perez; Dr Alexandra Monnier, Dr Christine Kummerlen, Dr Hamid Merdij, Dr Hassene Rahmani, Dr Julie Helms, Dr Laure Stiel, Dr Raphael Clere-Jehl and Dr Yannick Rabouel; Dr Jean-Pierre Quenot, Dr Audrey Large, Dr Auguste Dargent and Dr Pascal Andreu; Dr Damien Contou, Dr Elsa Logre, Dr Hervé Mentec, Dr Jean-Pierre Laforet, Dr Olivier Pajot and Dr Radj Cally; Dr Saadalla Nseir, Dr Anne Sophie Moreau, Dr Geoffrey Ledoux, Dr Julien Poissy, Dr Laurent Robriguet, Dr Marion Houard, Dr Olivier Pouly, Dr Raphael Favory, Dr Sophie Six and Dr Thibault Duburcq.

Contributors P-FL, BF, MSG, EL and TvdP designed and delivered the SEPCELL clinical trial. TDYR, JMB, BPS and TvdP conceived and designed the host response ancillary analyses. P-FL, BF, MSG, TDYR, TSRvE, KJG, DVO and DS contributed to the acquisition and quality control of the clinical and/or biological data. TDYR, JMB and KJG performed the analyses. TDYR and TvdP drafted the manuscript. All authors critically revised and approved the manuscript.

Funding This study was supported by a grant from the European Union's Horizon 2020 Research and Innovation Program (agreement number 681031) and sponsored by TiGenix SAU (a wholly owned subsidiary of Takeda Pharmaceuticals). TDYR is supported by the research programme 'NACTAR', project 'MDR-phage' (grant number 16447), which is financed by the Dutch Research Council (NWO).

Competing interests DVO, KJG and EL are employed by Takeda Pharmaceuticals, which produces Cx611.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the independent ethics committees of the participating hospitals: Comite de Protection des Personnes Sud-Ouest et Outre-Mer II, Agence Régionale de Santé Occitanie (Dossier 2-18-08); Comité d'Éthique Hospitalo Facultaire, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (2015/13NOV/618); Comité Ética Regional de la Comunidad de Madrid (Cx611-0204/2015-002994-39). Written informed consent was obtained from all patients, their legal representative or next of

kin. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement RNAseq data are available from the NCBI Sequence Read Archive (SRA) under the BioProject accession PRJNA1097551. Other data generated and/or analysed during the current study are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Tom D Y Reijnders http://orcid.org/0000-0002-1764-0114 Tom van der Poll http://orcid.org/0000-0002-9199-5079

REFERENCES

- 1 Shaw TD, Krasnodembskaya AD, Schroeder GN, et al. Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases. Clin Microbiol Rev 2021;34:e00064-21.
- 2 Wang F, Li Y, Wang B, et al. The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Crit Care 2023;27:1–11.
- 3 Sun J, Ding X, Sun T. Mesenchymal Stem Cells in Sepsis: From Basic Research to Clinical Application. *ICRES* 2021;1:2.
- 4 Laterre P-F, Sánchez-García M, van der Poll T, et al. A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit. BMC Pulm Med 2020;20:309.
- 5 Laterre P-F, Sánchez García M, van der Poll T, et al. The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial. J Crit Care 2024;79:154446.
- 6 Schlosser K, Wang J-P, Dos Santos C, et al. Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients. Crit Care Med 2019;47:918–25.
- 7 Kaffash Farkhad N, Sedaghat A, Reihani H, et al. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res Ther 2022;13:1–13.
- 8 Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 2019;7:154–62.
- 9 Christy BA, Herzig MC, Montgomery RK, et al. Procoagulant activity of human mesenchymal stem cells. J Trauma Acute Care Surg 2017;83:S164–9.
- 10 Yang B, Long Y, Zhang A, et al. Procoagulant Properties of Mesenchymal Stem Cells and Extracellular Vesicles: a Novel Aspect of Thrombosis Pathogenesis. Stem Cells 2024;42:98–106.